Previous 10 | Next 10 |
Summary AMLX got relyvrio approved through an interesting set of events. There are questions surrounding high price, low benefit, trial design, and so on. However, simply the high demand from a vocal and very sick patient population may well save the day for the company. I...
The following slide deck was published by Amylyx Pharmaceuticals, Inc. in conjunction with this event. For further details see: Amylyx Pharmaceuticals (AMLX) Investor Presentation - Slideshow
Amylyx Pharmaceuticals ( NASDAQ: AMLX ) said that initial sales of its amyotrophic lateral sclerosis treatment, Relyvrio, approved in late September 2022, are much better than expected and will exceed consensus. Relyvrio (taurursodiol and sodium phenylbutyrate) comes with a ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX), today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the SVB Securities Global Biopharma Conference. The conference is being conducted in a virtual format, and the fireside chat will take place on Tuesday, February ...
- Topline results expected in 2024 Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the completion of enrollment in PHOENIX, a global, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium pheny...
Amylyx Pharmaceuticals ( NASDAQ: AMLX ) and Neopharm have signed an agreement to commercialize the former’s FDA-approved treatment for amyotrophic lateral sclerosis (ALS) AMX0035 in regions including Israel. According to the deal, Amylyx ( AMLX ) will give exclusive rights ...
- Neopharm gains exclusive rights to commercialize AMX0035 in Israel, Gaza, West Bank, and the Palestinian Authority - Agreement marks Amylyx’ first distribution partnership since AMX0035 regulatory approvals and commercial launches in the U.S. and Canada Amylyx Pharmaceuticals...
Summary Halvorsen's 13F portfolio value decreased marginally from $21.86B to $21.66B this quarter. The number of positions increased from 82 to 88. Viking Global increased Elevance Health, Visa, and McKesson while decreasing T-Mobile US, Parker Hannifin, and Fortive. They also dropped A...
Summary Amylyx Pharmaceuticals, Inc. received a surprise approval for Relyvrio in ALS. The approval is great for the once-small company. However, its impact on the future of Amylyx Pharmaceuticals remains unpredictable. In March, after I wrote that Amylyx Pharmaceutica...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual HealthCONx Conference. The conference is being conducted in a virtual format, and the fireside chat will take place on Tuesda...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...